PI3K/Akt/mTOR inhibitors in breast cancer
Activation of the phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is common in breast cancer. There is preclinical data to support inhibition of the pathway, and phase I to Ⅲ trials involving inhibitors of the pathway have been or are being conducted in solid tumors...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
China Anti-Cancer Association
2015-12-01
|
Series: | Cancer Biology & Medicine |
Subjects: | |
Online Access: | http://www.cancerbiomed.org/index.php/cocr/article/view/888 |